Optimal seasonal timing of infant immunisation to prevent RSV hospitalisations in Japan: a modelling study

A modeling study in Japan suggests that while both year-round and seasonal catch-up immunization strategies using maternal RSVpreF vaccines or nirsevimab monoclonal antibodies could substantially reduce infant RSV hospitalizations compared to current high-risk-only protocols, the optimal approach depends on the predictability of seasonal circulation and the duration of protection provided by the interventions.

The Gist

Imagine Japan as a giant playground where a sneaky, invisible bully named RSV (Respiratory Syncytial Virus) shows up every year to pick on the youngest kids. This bully is very predictable: it usually hangs around during the cold winter months, causing kids to get sick enough to end up in the hospital.

For a long time, the playground only had a rule to protect the "special needs" kids (those with health problems) from this bully. But now, we have two powerful new super-shields:

1. The Mom's Shield (RSVpreF): A vaccine given to pregnant moms that passes a temporary forcefield to the baby.
2. The Magic Wand (Nirsevimab): A long-acting antibody shot given directly to the baby.

The big question this study asks is: When is the best time to hand out these shields?

The Two Strategies

Strategy A: The "Always Ready" Approach (Year-Round)
Imagine a security guard who hands out a shield to every single baby the moment they are born, no matter what time of year it is.

• The Good: Every baby is protected immediately.
• The Bad: Some babies get their shield in the summer when the bully isn't even there. By the time winter comes, that shield might have faded away (like a battery losing charge), leaving the baby vulnerable just when they need it most.

Strategy B: The "Seasonal Timing" Approach (Catch-Up)
This is like a smart scheduler. If a baby is born in the summer (when the bully is sleeping), we wait. We don't give them the shield yet. Instead, we wait until the first signs of winter appear, and then we rush to give them the shield (a "catch-up" dose) right before the bully wakes up.

• The Good: The shield is fresh and strong exactly when the bully attacks.
• The Bad: It requires perfect timing. If you guess the winter wrong, or if the logistics of rushing to give shots are too hard, it might not work as well.

What the Scientists Found

The researchers built a computer simulation (a "digital playground") using data from Japan to see which strategy works best. Here is what they discovered:

1. Both shields are amazing: Whether you use the Mom's Shield or the Magic Wand, protecting babies could cut down hospital visits by nearly half (46% to 58%) compared to doing nothing new.
2. Timing is tricky: The "Seasonal Timing" strategy (waiting to give the shot) is slightly better than the "Always Ready" strategy, but only if you can predict exactly when winter starts.
   • Think of it like surfing. If you paddle out and catch the wave at the perfect second, you ride it beautifully. But if you paddle out too early, you get tired waiting; if you paddle out too late, you miss the wave.
   • The study found that if the timing is perfect, the seasonal approach is about 10% to 20% more effective than just giving shots to everyone at birth.
3. The "Battery Life" Factor: The Magic Wand (nirsevimab) is special because its battery lasts a long time. If the battery lasts longer than six months, the "Always Ready" strategy becomes the winner because the shield stays strong even if the baby is born in the summer.

The Bottom Line

This study tells us that Japan has a golden opportunity to stop many babies from getting sick with RSV.

• The Ideal Scenario: If we can perfectly predict when the virus will return, waiting to give the shot just before the season starts is the most efficient way to use our resources.
• The Reality Check: However, nature can be unpredictable. If the virus arrives earlier or later than expected, or if it's too hard to organize a "catch-up" rush, simply giving the shot to every baby at birth is still a very strong, safe, and effective plan.

In short: Giving the shields works wonders. Whether we give them immediately at birth or wait for the "winter season" depends on how well we can predict the weather and how long the shields last.

Technical Summary

1. Problem Statement

Respiratory Syncytial Virus (RSV) exhibits distinct seasonal circulation patterns in Japan. Current strategies for infant protection involve passive immunity via maternal vaccination (RSVpreF) or long-acting monoclonal antibodies (nirsevimab). However, these interventions offer only transient protection.

The core challenge addressed by the study is determining the optimal timing for immunization. Specifically, the authors investigate whether a year-round administration strategy (vaccinating all infants at birth regardless of season) is superior to a seasonal and catch-up strategy. The latter involves deferring immunization for infants born during the RSV inter-seasonal period until they enter their first RSV season, utilizing catch-up administration. The goal is to maximize the reduction of RSV-related infant hospitalizations while accounting for the waning of immunity and the predictability of seasonal peaks.

2. Methodology

The researchers employed a static cohort model to simulate the first year of life for infants in Japan. The study utilized the following data sources and analytical techniques:

• Data Parameterization:
  • Incidence Data: Weekly and municipality-specific RSV incidence rates in Japan from 2018 to 2025.
  • Hospitalization Risk: Data derived from a health claims database study to estimate the risk of hospitalization given an RSV case.
  • Intervention Efficacy: Bayesian inference was used to estimate the effectiveness and the rate of waning for both RSVpreF (maternal vaccine) and nirsevimab (monoclonal antibody) based on clinical trial data.
• Comparative Scenarios:
  • Status Quo: Current practice where only high-risk infants receive monoclonal antibodies.
  • Year-Round Programme: Universal administration at birth.
  • Seasonal & Catch-Up Programme: Deferring immunization for inter-seasonal births until the onset of the RSV season, followed by catch-up administration.
• Analysis: The model compared the percentage reduction in hospitalizations across these strategies, incorporating uncertainty ranges (UR) to account for variability in seasonality and efficacy.

3. Key Contributions

• Context-Specific Modeling: This is one of the first studies to model RSV intervention strategies specifically for the Japanese demographic and epidemiological context, utilizing granular municipality-level data.
• Strategic Comparison: It provides a quantitative framework comparing "birth-based" (year-round) versus "seasonality-based" (catch-up) immunization strategies, addressing the logistical and clinical trade-offs of each.
• Waning Immunity Consideration: The model explicitly accounts for the transient nature of passive immunity, analyzing how the duration of protection (specifically beyond six months) influences the optimal strategy.

4. Key Results

The study yielded the following quantitative findings regarding the reduction of RSV infant hospitalizations compared to the status quo:

• Year-Round Efficacy:
  • RSVpreF: Projected to reduce hospitalizations by 46% (95% UR: 31%–65%).
  • Nirsevimab: Projected to reduce hospitalizations by 58% (95% UR: 39%–79%).
• Seasonal vs. Year-Round Comparison:
  • When comparing seasonal/catch-up programmes directly against year-round programmes, the seasonal approach achieved a 1.1-fold (95% UR: 0.82–1.6) reduction for RSVpreF and a 0.98-fold (95% UR: 0.83–1.2) reduction for nirsevimab.
  • Timing Sensitivity: If the seasonal immunization timing perfectly matches the RSV season (using 2024 as a case example), the seasonal programme showed a 1.2-fold (95% UR: 0.95–1.6) improvement for RSVpreF and a 1.1-fold (95% UR: 0.97–1.2) improvement for nirsevimab over the year-round approach.
• Critical Condition for Year-Round Superiority: The study found that if the protection provided by nirsevimab remains substantial beyond six months, the year-round programme becomes the more effective strategy, negating the need for complex catch-up logistics.

5. Significance and Implications

• Public Health Impact: Both RSVpreF and nirsevimab have the potential to substantially reduce the burden of RSV hospitalizations in Japan, regardless of the specific timing strategy chosen.
• Strategic Decision Making: The choice between a year-round and a seasonal strategy is highly dependent on two factors:
  1. Predictability of Seasonality: Seasonal strategies are only superior if the RSV season is predictable and immunization can be timed precisely.
  2. Duration of Protection: If monoclonal antibodies provide protection longer than six months, the logistical complexity of a seasonal catch-up programme may not be justified, as a simple year-round birth administration would yield better or equal results.
• Logistical Considerations: While seasonal programmes offer theoretical efficiency gains in specific timing scenarios, the study highlights that logistical challenges in implementing catch-up campaigns may offset these benefits.

In conclusion, the study suggests that while seasonal timing offers marginal theoretical advantages under ideal conditions, a robust year-round programme remains a highly effective and potentially more feasible strategy, particularly if the duration of antibody protection is confirmed to be long-lasting.